Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System

Objectives: Intraocular administration of vascular endothelial growth factor (VEGF) inhibitors may be associated with pregnancy loss. However, little is known about intraocular anti-VEGF therapy during pregnancy. Here, we conducted a pharmacovigilance study using a spontaneous reporting database to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Takamasa, Mori, Chiyo, Ohtsu, Fumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684212/
https://www.ncbi.nlm.nih.gov/pubmed/36438807
http://dx.doi.org/10.3389/fphar.2022.1063625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684212/
https://www.ncbi.nlm.nih.gov/pubmed/36438807
http://dx.doi.org/10.3389/fphar.2022.1063625

Ejemplares similares